Sugi Predict

Sugi Predict / Compounds / SCHEMBL19549702

SCHEMBL19549702

SCHEMBL19549702

Cc1c(C2=CCCCC2)cccc1-c1nc2c(s1)CNCC2

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDCD1 Q15116 15/20 0.70
▸ CD274 Q9NZQ7 15/20 0.70
▸ TLR9 Q9NR96 1/20 0.37
▸ TLR8 Q9NR97 1/20 0.37
▸ TLR7 Q9NYK1 1/20 0.37
▸ PSMB5 P28074 1/20 0.34
▸ APEX1 P27695 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19549761 0.83 PDCD1 (1.00) PDCD1CD274TLR9TLR8TLR7
SCHEMBL30504422 0.80 CD274 (0.68) PDCD1CD274TLR9TLR8TLR7
SCHEMBL19549722 0.80 PDCD1 (0.82) PDCD1CD274
SCHEMBL20324274 0.79 PDCD1 (0.66) PDCD1CD274TLR9TLR8TLR7
SCHEMBL19549737 0.76 PDCD1 (1.00) PDCD1CD274TLR9TLR8TLR7
SCHEMBL30504452 0.76 CD274 (0.63) PDCD1CD274TLR9TLR8TLR7
SCHEMBL19549760 0.75 CD274 (0.71) PDCD1CD274TLR9TLR8TLR7
SCHEMBL19549699 0.74 PDCD1 (1.00) PDCD1CD274TLR9TLR8TLR7
SCHEMBL19549669 0.74 CD274 (0.77) PDCD1CD274TLR9TLR8TLR7
SCHEMBL14305113 0.73 PDCD1 (0.58) PDCD1CD274TLR9TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11608337-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-03-21 — — US claimed
EP-3452476-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Holdings Corporation (US) 2019-03-13 — — EP claimed
US-20190071439-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2019-03-07 — — US claimed
WO-2017192961-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2017-11-09 — — WO claimed
US-20170320875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-11-09 — — US claimed
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-06-22 — — US disclosed
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-06-22 — — US disclosed
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-06-22 — — US disclosed
US-11608337-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-03-21 — — US disclosed
EP-3452476-B1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2021-12-15 — — EP disclosed
US-20210017175-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2021-01-21 — — US disclosed
US-20210017175-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2021-01-21 — — US disclosed
US-20200172541-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2020-06-04 — — US disclosed
US-20200172541-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2020-06-04 — — US disclosed
US-20190071439-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2019-03-07 — — US disclosed
US-20190071439-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2019-03-07 — — US disclosed
US-20170320875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-11-09 — — US disclosed
WO-2017192961-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION (US) 2017-11-09 — — WO disclosed
US-20170320875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-11-09 — — US disclosed
US-20170320875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2017-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS PDCD1 157/4885CD274 88/4885TLR9 112/4885
US-20190071439-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS PDCD1 157/4885CD274 88/4885TLR9 112/4885
US-20170320875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS PDCD1 157/4885CD274 88/4885TLR9 112/4885
US-20200172541-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS PDCD1 157/4885CD274 88/4885TLR9 112/4885
US-11608337-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS PDCD1 157/4885CD274 88/4885TLR9 112/4885
US-20210017175-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS PDCD1 157/4885CD274 88/4885TLR9 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.